Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations

Journal of Allergy and Clinical Immunology

Volumn 141, Issue 6, 2018, Pages 2142-2155.e5

  Vargas Hernández, Alexander ^a,b   Mace, Emily M ^a,b   Zimmerman, Ofer ^c   Zerbe, Christa S ^c,d   Freeman, Alexandra F ^c,d   Rosenzweig, Sergio ^c,d   Leiding, Jennifer W ^e   Torgerson, Troy ^f   Altman, Matthew C ^f   Schussler, Edith ^g   Cunningham Rundles, Charlotte ^g   Chinn, Ivan K ^a,b   Carisey, Alexandre F ^a,b   Hanson, Imelda C ^a   Rider, Nicholas L ^a,b   Holland, Steven M ^c,d   Orange, Jordan S ^a,b   Forbes, Lisa R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Janus kinase inhibition; natural killer cell deficiency; natural killer cell maturation; perforin; ruxolitinib; Signal transducer and activator of transcription 1, gain of function

Indexed keywords

CD16 ANTIGEN; CD57 ANTIGEN; INTERLEUKIN 2; JANUS KINASE 1; JANUS KINASE 2; PERFORIN; RUXOLITINIB; STAT1 PROTEIN; STAT5 PROTEIN; JANUS KINASE; PYRAZOLE DERIVATIVE; STAT1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; DENDRITIC CELL; ENHANCER REGION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE EDITING; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; IN VITRO STUDY; LYMPHOCYTOPENIA; MALE; MYCOSIS; NATURAL KILLER CELL; NK-92 CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; SEX RATIO; T LYMPHOCYTE; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; GENETICS; IMMUNE DEFICIENCY; IMMUNOLOGY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GAIN OF FUNCTION MUTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; JANUS KINASES; KILLER CELLS, NATURAL; MALE; PYRAZOLES; STAT1 TRANSCRIPTION FACTOR;

EID: 85043254118     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.08.040     Document Type: Article

References (66)

1. Cooper, M.A., Fehniger, T.A., Caligiuri, M.A., The biology of human natural killer-cell subsets. Trends Immunol 22 (2001), 633–640.
2. Biron, C.A., Nguyen, K.B., Pien, G.C., Cousens, L.P., Salazar-Mather, T.P., Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17 (1999), 189–220.
3. Caligiuri, M.A., Human natural killer cells. Blood 112 (2008), 461–469.
4. Cooper, M.A., Fehniger, T.A., Turner, S.C., Chen, K.S., Ghaheri, B.A., Ghayur, T., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 (2001), 3146–3151.
5. Poli, A., Michel, T., Theresine, M., Andres, E., Hentges, F., Zimmer, J., CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126 (2009), 458–465.
6. Freud, A.G., Becknell, B., Roychowdhury, S., Mao, H.C., Ferketich, A.K., Nuovo, G.J., et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22 (2005), 295–304.
7. Freud, A.G., Caligiuri, M.A., Human natural killer cell development. Immunol Rev 214 (2006), 56–72.
8. Fan, Y.Y., Yang, B.Y., Wu, C.Y., Phenotypically and functionally distinct subsets of natural killer cells in human PBMCs. Cell Biol Int 32 (2008), 188–197.
9. Wilk, E., Kalippke, K., Buyny, S., Schmidt, R.E., Jacobs, R., New aspects of NK cell subset identification and inference of NK cells’ regulatory capacity by assessing functional and genomic profiles. Immunobiology 213 (2008), 271–283.
10. Freud, A.G., Yokohama, A., Becknell, B., Lee, M.T., Mao, H.C., Ferketich, A.K., et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203 (2006), 1033–1043.
11. Grzywacz, B., Kataria, N., Sikora, M., Oostendorp, R.A., Dzierzak, E.A., Blazar, B.R., et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108 (2006), 3824–3833.
12. Frey, M., Packianathan, N.B., Fehniger, T.A., Ross, M.E., Wang, W.C., Stewart, C.C., et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol 161 (1998), 400–408.
13. Miller, J.S., McCullar, V., Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 98 (2001), 705–713.
14. Sivori, S., Cantoni, C., Parolini, S., Marcenaro, E., Conte, R., Moretta, L., et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 33 (2003), 3439–3447.
15. Yu, J., Mao, H.C., Wei, M., Hughes, T., Zhang, J., Park, I.K., et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115 (2010), 274–281.
16. Bjorkstrom, N.K., Riese, P., Heuts, F., Andersson, S., Fauriat, C., Ivarsson, M.A., et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116 (2010), 3853–3864.
17. Addison, E.G., North, J., Bakhsh, I., Marden, C., Haq, S., Al-Sarraj, S., et al. Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology 116 (2005), 354–361.
18. Lopez-Verges, S., Milush, J.M., Pandey, S., York, V.A., Arakawa-Hoyt, J., Pircher, H., et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116 (2010), 3865–3874.
19. Cichocki, F., Miller, J.S., Anderson, S.K., Bryceson, Y.T., Epigenetic regulation of NK cell differentiation and effector functions. Front Immunol, 4, 2013, 55.
20. Huntington, N.D., Legrand, N., Alves, N.L., Jaron, B., Weijer, K., Plet, A., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206 (2009), 25–34.
21. Becknell, B., Caligiuri, M.A., Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86 (2005), 209–239.
22. Tamzalit, F., Barbieux, I., Plet, A., Heim, J., Nedellec, S., Morisseau, S., et al. IL-15.IL-15Ralpha complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Proc Natl Acad Sci U S A 111 (2014), 8565–8570.
23. Mace, E.M., Orange, J.S., Genetic causes of human NK cell deficiency and their effect on NK cell subsets. Front Immunol, 7, 2016, 545.
24. Mace, E.M., Bigley, V., Gunesch, J.T., Chinn, I.K., Angelo, L.S., Care, M.A., et al. Biallelic mutations in IRF8 impair human NK cell maturation and function. J Clin Invest 127 (2017), 306–320.
25. Mace, E.M., Hsu, A.P., Monaco-Shawver, L., Makedonas, G., Rosen, J.B., Dropulic, L., et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 121 (2013), 2669–2677.
26. Gineau, L., Cognet, C., Kara, N., Lach, F.P., Dunne, J., Veturi, U., et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest 122 (2012), 821–832.
27. Hughes, C.R., Guasti, L., Meimaridou, E., Chuang, C.H., Schimenti, J.C., King, P.J., et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 122 (2012), 814–820.
28. Orange, J.S., Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8 (2008), 713–725.
29. Orange, J.S., Natural killer cell deficiency. J Allergy Clin Immunol 132 (2013), 515–526.
30. Grier, J.T., Forbes, L.R., Monaco-Shawver, L., Oshinsky, J., Atkinson, T.P., Moody, C., et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 122 (2012), 3769–3780.
31. Vairo, D., Tassone, L., Tabellini, G., Tamassia, N., Gasperini, S., Bazzoni, F., et al. Severe impairment of IFN-gamma and IFN-alpha responses in cells of a patient with a novel STAT1 splicing mutation. Blood 118 (2011), 1806–1817.
32. Tabellini, G., Vairo, D., Scomodon, O., Tamassia, N., Ferraro, R.M., Patrizi, O., et al. Impaired NK cell functions in patients with STAT1 gain-of-function mutations. J Allergy Clin Immunol 140 (2017), 553–564.e4.
33. Levy, D.E., Darnell, J.E. Jr., Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002), 651–662.
34. Ma, A., Koka, R., Burkett, P., Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 24 (2006), 657–679.
35. Rochman, Y., Spolski, R., Leonard, W.J., New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9 (2009), 480–490.
36. Reich, N.C., STAT dynamics. Cytokine Growth Factor Rev 18 (2007), 511–518.
37. Schindler, C., Fu, X.Y., Improta, T., Aebersold, R., Darnell, J.E. Jr., Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci U S A 89 (1992), 7836–7839.
38. Gutch, M.J., Daly, C., Reich, N.C., Tyrosine phosphorylation is required for activation of an alpha interferon-stimulated transcription factor. Proc Natl Acad Sci U S A 89 (1992), 11411–11415.
39. Greenlund, A.C., Morales, M.O., Viviano, B.L., Yan, H., Krolewski, J., Schreiber, R.D., Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. Immunity 2 (1995), 677–687.
40. Villarino, A.V., Kanno, Y., Ferdinand, J.R., O'Shea, J.J., Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 194 (2015), 21–27.
41. Tweardy, D.J., Wright, T.M., Ziegler, S.F., Baumann, H., Chakraborty, A., White, S.M., et al. Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. Blood 86 (1995), 4409–4416.
42. Gotthardt, D., Sexl, V., STATs in NK-cells: the good, the bad, and the ugly. Front Immunol, 7, 2016, 694.
43. Zhang, J., Scordi, I., Smyth, M.J., Lichtenheld, M.G., Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med 190 (1999), 1297–1308.
44. Yu, C.R., Ortaldo, J.R., Curiel, R.E., Young, H.A., Anderson, S.K., Gosselin, P., Role of a STAT binding site in the regulation of the human perforin promoter. J Immunol 162 (1999), 2785–2790.
45. Yamamoto, K., Shibata, F., Miyasaka, N., Miura, O., The human perforin gene is a direct target of STAT4 activated by IL-12 in NK cells. Biochem Biophys Res Commun 297 (2002), 1245–1252.
46. Imada, K., Bloom, E.T., Nakajima, H., Horvath-Arcidiacono, J.A., Udy, G.B., Davey, H.W., et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 188 (1998), 2067–2074.
47. Hwa, V., Nadeau, K., Wit, J.M., Rosenfeld, R.G., STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab 25 (2011), 61–75.
48. Liu, L., Okada, S., Kong, X.F., Kreins, A.Y., Cypowyj, S., Abhyankar, A., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208 (2011), 1635–1648.
49. van de Veerdonk, F.L., Plantinga, T.S., Hoischen, A., Smeekens, S.P., Joosten, L.A., Gilissen, C., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365 (2011), 54–61.
50. Takezaki, S., Yamada, M., Kato, M., Park, M.J., Maruyama, K., Yamazaki, Y., et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 189 (2012), 1521–1526.
51. Sampaio, E.P., Hsu, A.P., Pechacek, J., Bax, H.I., Dias, D.L., Paulson, M.L., et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 131 (2013), 1624–1634.
52. Toth, B., Mehes, L., Tasko, S., Szalai, Z., Tulassay, Z., Cypowyj, S., et al. Herpes in STAT1 gain-of-function mutation [corrected]. Lancet, 379, 2012, 2500.
53. Uzel, G., Sampaio, E.P., Lawrence, M.G., Hsu, A.P., Hackett, M., Dorsey, M.J., et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131 (2013), 1611–1623.
54. Toubiana, J., Okada, S., Hiller, J., Oleastro, M., Lagos Gomez, M., Aldave Becerra, J.C., et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127 (2016), 3154–3164.
55. Orange, J.S., Ramesh, N., Remold-O'Donnell, E., Sasahara, Y., Koopman, L., Byrne, M., et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 99 (2002), 11351–11356.
56. Gong, J.H., Maki, G., Klingemann, H.G., Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8 (1994), 652–658.
57. Yodoi, J., Teshigawara, K., Nikaido, T., Fukui, K., Noma, T., Honjo, T., et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol 134 (1985), 1623–1630.
58. Shaw, R.K., Issekutz, A.C., Fraser, R., Schmit, P., Morash, B., Monaco-Shawver, L., et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 119 (2012), 4009–4012.
59. Yang, X.P., Ghoreschi, K., Steward-Tharp, S.M., Rodriguez-Canales, J., Zhu, J., Grainger, J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12 (2011), 247–254.
60. Higgins, E., Al Shehri, T., McAleer, M.A., Conlon, N., Feighery, C., Lilic, D., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135 (2015), 551–553.
61. Mossner, R., Diering, N., Bader, O., Forkel, S., Overbeck, T., Gross, U., et al. Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Clin Infect Dis 62 (2016), 951–953.
62. Weinacht, K.G., Charbonnier, L.M., Alroqi, F., Plant, A., Qiao, Q., Wu, H., et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol 139 (2017), 1629–1640.e2.
63. Juelke, K., Killig, M., Luetke-Eversloh, M., Parente, E., Gruen, J., Morandi, B., et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116 (2010), 1299–1307.
64. Stray-Pedersen, A., Sorte, H.S., Samarakoon, P., Gambin, T., Chinn, I.K., Coban Akdemir, Z.H., et al. Primary immunodeficiency diseases: genomic approaches delineate heterogeneous Mendelian disorders. J Allergy Clin Immunol 139 (2017), 232–245.
65. Vignesh, P., Rawat, A., Singh, S., An update on the use of immunomodulators in primary immunodeficiencies. Clin Rev Allergy Immunol 52 (2017), 287–303.
66. Milner, J.D., Vogel, T.P., Forbes, L., Ma, C.A., Stray-Pedersen, A., Niemela, J.E., et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125 (2015), 591–599.